| Literature DB >> 24795069 |
Regina García-Delgado1, Dunia de Miguel2, Alicia Bailén3, José Ramón González4, Joan Bargay5, José F Falantes6, Rafael Andreu7, Fernando Ramos8, Mar Tormo9, Salut Brunet10, Antonio Figueredo11, Javier Casaño12, Angeles Medina13, Llorenç Badiella14, Antonio Fernández Jurado15, Guillermo Sanz16.
Abstract
We investigated the effectiveness and tolerability of azacitidine in patients with World Health Organization-defined myelodysplastic syndromes, or acute myeloid leukemia with 20-30% bone marrow blasts. Patients were treated with azacitidine, with one of three dosage regimens: for 5 days (AZA 5); 7 days including a 2-day break (AZA 5-2-2); or 7 days (AZA 7); all 28-day cycles. Overall response rates were 39.4%, 67.9%, and 51.3%, respectively, and median overall survival (OS) durations were 13.2, 19.1, and 14.9 months. Neutropenia was the most common grade 3-4 adverse event. These results suggest better effectiveness-tolerability profiles for 7-day schedules.Entities:
Keywords: Acute myeloid leukemia; Azacitidine; Dosing schedules; Myelodysplastic syndromes; Overall survival; Safety
Mesh：
Substances：
Year: 2014 PMID： 24795069 DOI： 10.1016/j.leukres.2014.03.004
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156